KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Enterprise Value (2016 - 2026)

Pacira BioSciences has reported Enterprise Value over the past 17 years, most recently at -$202.2 million for Q1 2026.

  • For Q1 2026, Enterprise Value rose 59.04% year-over-year to -$202.2 million; the TTM value through Mar 2026 reached -$202.2 million, up 59.04%, while the annual FY2025 figure was -$238.4 million, 50.8% up from the prior year.
  • Enterprise Value for Q1 2026 was -$202.2 million at Pacira BioSciences, up from -$238.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$174.0 million in Q1 2023 and troughed at -$493.6 million in Q1 2025.
  • A 5-year average of -$328.8 million and a median of -$316.4 million in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 61.52% in 2023 and later crashed 92.96% in 2024.
  • Year by year, Enterprise Value stood at -$288.7 million in 2022, then rose by 3.49% to -$278.6 million in 2023, then tumbled by 73.96% to -$484.6 million in 2024, then skyrocketed by 50.8% to -$238.4 million in 2025, then grew by 15.2% to -$202.2 million in 2026.
  • Business Quant data shows Enterprise Value for PCRX at -$202.2 million in Q1 2026, -$238.4 million in Q4 2025, and -$246.3 million in Q3 2025.